



HHS Public Access

Author manuscript

Pediatr Diabetes. Author manuscript; available in PMC 2017 July 01.

Published in final edited form as:

Pediatr Diabetes. 2016 July ; 17(Suppl 22): 31–36. doi:10.1111/pedi.12388.

Insulinitis in the Pathogenesis of Type 1 Diabetes

Alberto Pugliese, MD

Diabetes Research Institute, Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Microbiology and Immunology, University of Miami Miller School of Medicine, 1450 NW 10th Avenue, Miami, FL 33136 USA, Tel. 305-243-5348, Fax 305-243-4404

Alberto Pugliese: apuglies@med.miami.edu

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease in which autoreactive T-cells and inflammation cause severe loss of pancreatic beta cells. Insulinitis, the pathologic hallmark of T1D, is an inflammatory lesion consisting of immune cell infiltrates around and within the islets. New research initiatives and methodologies are advancing our understanding of pancreas pathology. Studies have revealed the predominant cellular types that infiltrate the islets, novel molecular aspects associated with insulinitis, and the coexistence of additional pathological abnormalities. While insulinitis is a critical element of T1D pathology and pathogenesis, it is typically present only in a modest proportion of islets at any given time, even at diagnosis, with overall limited relation to disease duration. Thus, the relative importance of insulinitis as a determining factor of diabetes symptoms at disease onset appears to have been overestimated; growing evidence also shows that beta cell loss at diagnosis is more modest than previously thought. Thus, the sole targeting of the immune system may not afford full therapeutic efficacy if dysfunction affects beta cells that are not under immune attack and this is a key contributor to symptoms. Combination therapies that promote both immunoregulation and address beta cell dysfunction should be more effective in treating this chronic disease process. It remains a major goal to clarify the relation of insulinitis with the dynamics of beta cell loss and coexisting mechanisms of dysfunction, according to clinical stage; such improved understanding is key to design therapeutic strategies that target multiple pathogenic mechanisms.

Keywords

Type 1 diabetes; insulinitis; beta cell; pancreas; autoimmunity

T1D is a multifactorial disease in which both genetic predisposition and environmental factors promote the triggering of autoimmune responses against pancreatic beta cells, which ultimately result in beta cell destruction and severe impairment of insulin secretion (1). Disease symptoms often manifest in children and adolescents, but patients are also diagnosed in adult age (2). Natural history studies have shown that the autoimmune process is triggered months and most often years prior to diagnosis (3). In studies of newborns from families with an affected individual or otherwise at genetic risk, the triggering of the autoimmune responses often occurs in early life, as assessed by the seroconversion for autoantibodies against islet cell autoantigens. Especially the presence of multiple autoantibodies is a strong predictor of future T1D. Differences in the natural history are

being appreciated in relation to age, and seroconversion may also be observed later in life (4, 5). Thus, the clinical diagnosis represents a moment in the disease natural history at which the consequences of the autoimmune responses are severe enough that the disease becomes clinically manifest.

T1D is considered a T-cell mediated autoimmune disease, and there are many lines of experimental, clinical and pathological evidence supporting this view (1). The pathologic hallmark of T1D has long been considered the inflammatory lesion of the pancreatic islets, which is termed insulinitis and is characterized by the presence of immune and inflammatory cells within and around the pancreatic islets (6). Insulinitis is the manifestation of the autoimmune attack against beta cells. Although Gepts described insulinitis more than 60 years ago (7), studies of insulinitis and other features of pancreas pathology in T1D have been limited by the scarce access to pancreata from T1D patients. The most extensive information about T1D pancreas pathology derives from the study of autopsy specimens obtained from patients near the time of diagnosis in the U.K. (8) and of biopsy specimens of living patients (the DiViD Study from Norway, and earlier studies from Japan) (9, 10); during the last decade, the JDRF has supported the launch of an organized effort in the U.S., the JDRF nPOD, to recover pancreas and other tissues from organ donors with T1D (11). This effort has allowed examining the pancreas with T1D throughout a much wider range of disease duration (12).

A consensus definition of the insulinitis lesion has been recently reported and should help focusing research efforts in the future (13); key elements of this definition are the presence of a predominantly lymphocytic infiltration of the islets of Langerhans, consisting of at least 15 CD45+ cells/islet and present in a minimum of three islets. Insulinitis can be found in the islet periphery (peri-insulinitis, often showing focal aggregation at one pole of the islet and in contact with the islet periphery) or within the islet parenchyma (intra-insulinitis); several studies indicate that the predominant form of insulinitis in the human pancreas is peri-insulinitis, and it is much less severe than in experimental mouse models (12, 14, 15). Insulinitis is most often detected in islets containing insulin-positive beta cells, but critically the same pancreas will also show pseudo-atrophic islets devoid of insulin-positive cells.

Investigators have examined the relative proportions of various infiltrating cell types in the insulinitis lesion and suggest that heterogeneous profiles may underlie disease severity and progression. While both T and B lymphocytes are reported in insulinitis lesions, cytotoxic CD8 T-cells appear to be the predominant population and could target beta cells expressing elevated levels of HLA class I molecules (8, 16–18); of note, hyper-expression of class I molecules (and class II molecules) may be associated with viral infections postulated to play a key role in T1D pathogenesis (19). Hyper-expression of HLA molecules represents another key feature in the pathology of the T1D that highlights a chronic inflammatory state; this is often associated with insulinitis (20). It is presently unknown whether islet-infiltrating CD8 T-cells can target viral epitopes presented by infected beta cells on their HLA class I molecules. However, studies of nPOD pancreata have demonstrated autoantigen-specific T-cells in the insulinitis lesion (21); these observations directly connect those autoreactive CD8 T-cells to the insulinitis and to disease pathogenesis. These studies also compared the diversity of the islet-infiltrating T-cell populations in relation to T1D duration, and reported increased

diversity in the antigen specificity of the infiltrating CD8 T-cells in patients with longer disease duration. Thus, the autoimmune response appears to evolve with time, even after diagnosis; these results also provide evidence for the chronicity of the process. Two distinct patterns of insulinitis were described in autopsy samples from U.K. patients with recent-onset T1D according to the prevalence of CD20 B-cells (CD20Hi and CD20Lo) (22); these findings were replicated in the nPOD and DiViD cohorts (23); the CD20Hi profile appears associated with an early age of diagnosis (7 years) while those diagnosed after age 13 have a CD20Lo insulinitis. Thus, the presence of higher proportions of B cells in the insulinitis lesion may be a marker of early triggering of autoimmunity or of a more rapid rate of beta cell loss.

The study of nPOD pancreata has identified some key molecular changes typical of insulinitis: these include the accumulation of hyaluronan, a key constituent of the extra-cellular matrix, and hyaluronan binding proteins, around islet cells and infiltrating lymphocytes in islets affected by insulinitis (24). These molecules may play a role in insulinitis by promoting lymphocyte adhesion and migration, and antagonizing hyaluronan deposition prevents diabetes in experimental mice (25–27). Moreover, cathepsins were found in the insulinitis lesion near areas of disruption of the peri-islet basement membrane, and may favor the penetration of lymphocytes inside the islets (28).

Overall, the proportion of islets showing insulinitis in the human T1D pancreas is quite low (~10–30%); this may vary to some extent by age and disease duration. Insulinitis appears more prevalent in younger patients and in those whose pancreas was examined nearer to diagnosis. For example, reports indicate that about 30% of insulin-positive islets are infiltrated in young patients who were recently diagnosed (6). In a study of biopsies performed in 6 patients with recent onset T1D (DiViD Study), aged 24–25 years, the proportions of islets affected by insulinitis varied significantly, ranging between 5 and 58%; of note, only 1 of the 6 patients had greater than 50% of the islets affected by insulinitis, and that occurred in 1 of the 2 sections analyzed (14, 29); on average, only 11% of the islets examined had insulinitis. Among 80 nPOD organ donors with variable duration of T1D, 17 had insulinitis with disease duration extending from diagnosis to 12 years, and age of onset ranging between 4 and 28 years. The frequency of insulinitis had limited inverse correlation with diabetes duration and no correlation with age at onset, or age at demise. Insulinitis predominantly affected insulin-positive islets (33% vs only 2% of insulin-negative islets). Importantly, insulinitis was observed in many patients, as well as residual beta cells, even many years after diagnosis (12).

Collectively, the available findings emphasize the chronicity of islet autoimmunity, which is present for several years after diagnosis in both children and young adults. All studies concur that insulinitis does not affect all islets at the same time, suggesting that this is a process that evolves over time. Moreover, both a meta-analysis of earlier data (30, 31) and recent findings argue that the long held belief that 90% of the beta cell mass is lost at diagnosis is no longer a tenable concept. Younger children are expected to have a greater loss, but those diagnosed when teenagers or older were reported to have at least 40%–60% of their islets staining positive for insulin (23, 30), including results from the U.K., nPOD and DiViD cohorts. The 6 DiViD biopsies were performed in adult patients with recent onset T1D: insulin staining was found in 18–66% and on average in 36% of the islets examined

(14). In the analysis of the 80 T1D nPOD donors, of whom only a few had disease duration less than 1 year (12), residual beta cells were observed in all T1D donors with insulinitis, who had on average a roughly 10-fold higher beta cell mass compared to those without insulinitis; there was no correlation of beta cell mass with insulinitis, disease duration and age of onset.

Thus, there appears to be some disconnect between the severe diabetes symptoms and impairment of insulin secretion at diagnosis and the emerging evidence suggesting limited insulinitis and only partial physical beta cell loss. This limited pathology has also been noted in recipients of pancreas transplants who had developed T1D recurrence in their grafts (32). There is increasing evidence that inflammation and beta cell dysfunction may be important pathogenic mechanisms at the time of the initial disease manifestation and contribute to cause the symptoms of severe hyperglycemia (33–37). Moreover, islet function may be recoverable (33), as shown by the DiViD study: islets isolated from the pancreas obtained via biopsy in newly diagnosed T1D recovered function in culture. This recognition has important implications for the design of therapeutic strategies to reverse diabetes at diagnosis. In fact, the low prevalence of insulinitis at diagnosis suggests that even at that time a therapy that attempts to deplete autoreactive T-cells may only be treating those islets with insulinitis, and therefore therapeutic efficacy may be limited. Combinatorial therapies should therefore address pathogenic cofactors, attempt to mitigate inflammation and correct beta cell dysfunction (38).

The above findings also suggest that beta cell destruction is quite heterogeneous and is not likely to be completed until several years after diagnosis. Studies have reported persistence of insulin-positive beta cells even decades after diagnosis (39–41) and that glucose transporters continue to be expressed (21, 42). There is evidence in some patients with long disease duration that beta cells express the survivin molecule, possibly a factor in the persistence of the beta cell phenotype (43). Low levels of beta cell apoptosis have been noted in the pancreas of patients with long disease duration, implying the existence of some beta cell turnover (39–41). The above observations are usually in the context of chronic signs of islet inflammation, including insulinitis and increased expression of HLA class I molecules (20).

Concordant with these observations, the assessment of functional beta cell mass through metabolic testing shows that stimulated C-peptide responses are often partially reduced in living patients (44–48), again with younger children showing more severe impairment. A prospective, post-diagnosis evaluation of C-peptide responses is being conducted in newly-diagnosed patients by the Type 1 Diabetes TrialNet; results so far have shown significant persistence of C-peptide, with about 80% of patients at 1 year and 60% at 2 years responding to a mixed meal with a peak C-peptide that would be suitable for randomization in a clinical trial at diagnosis; there is a slower decline in the second year after diagnosis, and not all patients experienced further decline of C-peptide secretion during the follow-up period (47). Several studies have reported that patients with decades of disease duration may secrete low amount of C-peptide and also respond with increased levels to stimulation (41, 49–51). Thus, both pathology data about insulinitis and beta cell mass and clinical data suggest that T1D is caused by a chronic disease process, which affects islets asynchronously continues its course over a long period of time after diagnosis.

There is much less information regarding the pathology of T1D during the prediabetic period. In fact, the relationships of insulinitis to autoantibody conversion and beta cell destruction during the prodromic period are essentially unknown. It would be critically important to establish if insulinitis is closely associated with the triggering or autoantibodies and/or circulating autoreactive T-cells; this would be of direct relevance to the design of prevention trials. Given that many individuals express autoantibodies for years prior to the eventual development of T1D, we need to understand whether this chronicity is due to a slow destructive process affecting a minority of islets over time or if at some point critical factors act as precipitants and may trigger insulinitis at a later stage. Prospective studies in relatives reveal that the triggering of islet autoimmune responses (autoantibodies) is eventually followed by the progressive impairment of insulin secretion and glucose metabolism; however, autoantibody-positive relatives may have normal metabolic measures for years, with abnormalities becoming apparent closer to diagnosis (52–54). Perhaps the actual destruction of beta cells is a late event that is triggered nearer to diagnosis, and perhaps autoantibody positivity per se does not necessarily imply the presence of insulinitis and beta cell loss (55). Such key questions may only be addressed if robust measures of islet inflammation, insulinitis, beta cell mass, and death can be developed and applied in longitudinal studies. Addressing these questions will require a combination of laboratory and imaging approaches (56–58).

Efforts are presently ongoing to identify pancreata from general population organ donors who test positive for T1D-associated autoantibodies, to determine the relationship of autoantibody positivity to pancreas pathology and especially the presence or absence of insulinitis. Such efforts are quite challenging, as the proportion of autoantibody-positive donors in the general population is very small. After pioneering studies demonstrated the feasibility of screening organ donors for autoantibodies (59, 60), the JDRF nPOD has launched a prospective, large-scale screening effort across the U.S. (11). So far pancreata from 18 donors who tested positive for autoantibodies have been recovered, of whom 13 expressed a single autoantibody, typically against the glutamic acid decarboxylase autoantigen (12). Donors with a single autoantibody do not typically carry HLA genes associated with increased T1D risk and do not appear to have insulinitis (12, 61). Thus, it is unclear if such donors should be considered as true pre-diabetic subjects, but there are increasing reports that their pancreas may show other abnormalities (11). nPOD identified 5 donors with multiple autoantibodies, and 2 had insulinitis in association with high-risk HLA types (12). Parallel efforts in Europe have conducted retrospective autoantibody screening of donors whose pancreas had been used for islet cell isolation, which typically would allow pathology evaluation of a small portion of the pancreas. One such study from Belgium identified 62 autoantibody-positive donors, and insulinitis was only found in 2 of the three donors with multiple autoantibodies, who also carried high-risk HLA types (62). Another study from Scandinavia identified 32 donors with autoantibodies, 9 of whom had multiple autoantibodies; yet none had high-risk HLA types and no insulinitis was found (63). We know that the presence of multiple autoantibodies is associated with much higher risk of progression to overt disease than positivity for a single autoantibody, and thus these findings may be related to the presence or absence of insulinitis. The specificity of the autoimmune response could also be important, but the number of autoantibody-positive donors reported

in the literature is too small to fully inform as whether particular autoantibody responses are closely associated with insulinitis. There is a need to study more of these rare cases, as the relation between insulinitis, beta cell loss, genetic predisposition and autoantibodies is critical to understand during the prediabetic period. Addressing these questions needs to account for the genetic, environmental and immunological heterogeneity of T1D.

In closing, the launch of programs aiming at the recovery and study of T1D and autoantibody-positive pancreata is leading to new discoveries about the pathology of human T1D; these findings also help identifying new therapeutic targets. Insulinitis remains a key element of T1D pathology, but it needs to be recognized that it is not the only pathogenic element; this has relevance for the design of clinical trials for more effective targeting of pathogenic mechanisms. Combination therapies that promote both immunoregulation and address beta cell dysfunction should be more effective in treating this chronic disease process. Future studies will reveal more of the phenotypic features of infiltrating cells in the insulinitis lesion, also in relation to other abnormalities, as well information about gene expression and epigenetic regulation of the beta cells, which is likely to be a major contributor to their dysfunction and ultimate fate. If the field stays the course, these efforts and improved clinical assessments in natural history studies will advance our understanding of the disease pathogenesis.

Acknowledgments

Studies by the author related to this topic were supported by grants from the National Institutes of Health (R01 DK070011), the JDRF (research grants 25-2013-268, 17-2011-594, 17-2012-3), The Leona M. and Harry B. Helmsley Charitable Trust (George Eisenbarth nPOD Award for Team Science, 2015PG-T1D052) and by the Diabetes Research Institute Foundation, Hollywood, Florida.

Abbreviations

T1D	Type 1 diabetes
JDRF	Juvenile Diabetes Research Foundation
nPOD	Network for the Pancreatic Organ Donor with Diabetes
DiViD	(Diabetes Virus Detection) Study
HLA	Human Leucocyte Antigen

References

1. Pugliese A. Advances in the etiology and mechanisms of type 1 diabetes. *Discovery medicine*. 2014; 18:141–50. [PubMed: 25227755]
2. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. *EndocrinolMetab ClinNorth Am*. 2010; 39:481–97.
3. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA*. 2013; 309:2473–9. [PubMed: 23780460]
4. Ziegler AG, Meier-Stiegen F, Winkler C, Bonifacio E. Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty - TEENDIAB: study design. *PediatrDiabetes*. 2011:10–5448.

5. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, et al. Development of autoantibodies in the TrialNet Natural History Study. *Diabetes Care*. 2011; 34:1897–901. [PubMed: 21750277]
6. In't Veld P. Insulinitis in human type 1 diabetes: The quest for an elusive lesion. *Islets*. 2011; 3:131–8. [PubMed: 21606672]
7. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. *Diabetes*. 1965; 14:619–33. [PubMed: 5318831]
8. Foulis AK, Liddle CN, Farwuharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in Type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. *Diabetologia*. 1986; 29:267–74. [PubMed: 3522324]
9. Krogvold L, Edwin B, Buanes T, Ludvigsson J, Korsgren O, Hyoty H, et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. *Diabetologia*. 2014; 57:841–3. [PubMed: 24429579]
10. Imagawa A, Hanafusa T, Tamura S, Moriwaki M, Itoh N, Yamamoto K, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. *Diabetes*. 2001; 50:1269–73. [PubMed: 11375326]
11. Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. *PediatrDiabetes*. 2014; 15:1–9.
12. Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulinitis and beta-Cell Mass in the Natural History of Type 1 Diabetes. *Diabetes*. 2015
13. Campbell-Thompson ML, Atkinson MA, Butler AE, Chapman NM, Frisk G, Gianani R, et al. The diagnosis of insulinitis in human type 1 diabetes. *Diabetologia*. 2013; 56:2541–3. [PubMed: 24006089]
14. Krogvold L, Wiberg A, Edwin B, Buanes T, Jahnsen FL, Hanssen KF, et al. Insulinitis and characterisation of infiltrating T cells in surgical pancreatic tail resections from patients at onset of type 1 diabetes. *Diabetologia*. 2016; 59:492–501. [PubMed: 26602422]
15. Reddy S, Zeng N, Al-Diery H, Jung D, Yeu C, Joret MO, et al. Analysis of peri-islet CD45-positive leucocytic infiltrates in long-standing type 1 diabetic patients. *Diabetologia*. 2015; 58:1024–35. [PubMed: 25687234]
16. Foulis AK, Farquharson MA, Hardman R. Aberant expression of class II major histocompatibility complex molecules by beta cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type I (insulin dependent) diabetes mellitus. *Diabetologia*. 1987; 30:333–43. [PubMed: 3301484]
17. Foulis AK, Farquharson MA. Aberrant expression of HLA-DR antigens by insulin containing beta cells in recent onset Type I (insulin dependent) diabetes mellitus. *Diabetes*. 1986; 35:1215–26. [PubMed: 3530850]
18. Bottazzo GF, Dean BM, McNally JM, Mackay EH, Swift PGF, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulinitis. *New Eng J Med*. 1985; 313:353–60. [PubMed: 3159965]
19. Krogvold L, Edwin B, Buanes T, Frisk G, Skog O, Anagandula M, et al. Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. *Diabetes*. 2015; 64:1682–7. [PubMed: 25422108]
20. Morgan NG, Leete P, Foulis AK, Richardson SJ. Islet inflammation in human type 1 diabetes mellitus. *IUBMB Life*. 2014; 66:723–34. [PubMed: 25504835]
21. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. *JExpMed*. 2012
22. Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estorninho M, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. *Diabetes*. 2014; 63:3835–45. [PubMed: 24939426]

23. Leete P, Willcox A, Krogvold L, Dahl-Jorgensen K, Foulis AK, Richardson SJ, et al. Differential insulinitic profiles determine the extent of beta cell destruction and the age at onset of type 1 diabetes. *Diabetes*. 2016
24. Bogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, et al. Hyaluronan and Hyaluronan Binding Proteins Accumulate in both Human Type 1 Diabetic Islets and Lymphoid Tissues and Associate with Inflammatory Cells in Insulinitis. *Diabetes*. 2014
25. Kuipers HF, Rieck M, Gurevich I, Nagy N, Butte MJ, Negrin RS, et al. Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization. *Proc Natl Acad Sci U S A*. 2016; 113:1339–44. [PubMed: 26787861]
26. Nagy N, Kaber G, Johnson PY, Gebe JA, Preisinger A, Falk BA, et al. Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulinitis. *The Journal of clinical investigation*. 2015; 125:3928–40. [PubMed: 26368307]
27. Bogdani M, Korpos E, Simeonovic CJ, Parish CR, Sorokin L, Wight TN. Extracellular matrix components in the pathogenesis of type 1 diabetes. *Current diabetes reports*. 2014; 14:552. [PubMed: 25344787]
28. Korpos E, Kadri N, Kappelhoff R, Wegner J, Overall CM, Weber E, et al. The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. *Diabetes*. 2013; 62:531–42. [PubMed: 23139348]
29. Krogvold L, Edwin B, Buanes T, Ludvigsson J, Korsgren O, Hyoty H, et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. *Diabetologia*. 2014
30. Klinke DJ. Extent of Beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. *PLoS ONE*. 2008; 3:e1374.
31. Klinke DJ. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. *PLoS One*. 2011; 6:e26873. [PubMed: 22073210]
32. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. *Diabetes*. 2010; 59:947–57. [PubMed: 20086230]
33. Krogvold L, Skog O, Sundstrom G, Edwin B, Buanes T, Hanssen KF, et al. Function of Isolated Pancreatic Islets From Patients at Onset of Type 1 Diabetes: Insulin Secretion Can Be Restored After Some Days in a Nondiabetogenic Environment In Vitro: Results From the DiViD Study. *Diabetes*. 2015; 64:2506–12. [PubMed: 25677915]
34. Marhfour I, Lopez XM, Lefkaditis D, Salmon I, Allagnat F, Richardson SJ, et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. *Diabetologia*. 2012; 55:2417–20. [PubMed: 22699564]
35. Imai Y, Dobrian AD, Morris MA, Taylor-Fishwick DA, Nadler JL. Lipids and immunoinflammatory pathways of beta cell destruction. *Diabetologia*. 2016
36. Burch TC, Morris MA, Campbell-Thompson M, Pugliese A, Nadler JL, Nyalwidhe JO. Proteomic Analysis of Disease Stratified Human Pancreas Tissue Indicates Unique Signature of Type 1 Diabetes. *PloS one*. 2015; 10:e0135663. [PubMed: 26302420]
37. Grzesik WJ, Nadler JL, Machida Y, Nadler JL, Imai Y, Morris MA. Expression pattern of 12-lipoxygenase in human islets with type 1 diabetes and type 2 diabetes. *The Journal of clinical endocrinology and metabolism*. 2015; 100:E387–95. [PubMed: 25532042]
38. Skyler JS. Prevention and reversal of type 1 diabetes—past challenges and future opportunities. *Diabetes care*. 2015; 38:997–1007. [PubMed: 25998292]
39. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? *Diabetologia*. 2005; 48:2221–8. [PubMed: 16205882]
40. Meier JJ, Ritzel RA, Maedler K, Gurlo T, Butler PC. Increased vulnerability of newly forming beta cells to cytokine-induced cell death. *Diabetologia*. 2005; 49:83–9. [PubMed: 16323002]
41. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual insulin production and pancreatic β -cell turnover after 50 years of diabetes: Joslin Medalist Study. *Diabetes*. 2010; 59:2846–53. [PubMed: 20699420]

42. Coppieters KT, Wiberg A, Amirian N, Kay TW, von Herrath MG. Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individuals. *Diabetes Metab ResRev.* 2011; 27:746–54.
43. Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. *Diabetologia.* 2010; 53:690–8. [PubMed: 20062967]
44. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. *Diabetologia.* 2006; 49:261–70. [PubMed: 16404554]
45. Sherry NA, Tsai EB, Herold KC. Natural History of β -Cell Function in Type 1 Diabetes. *Diabetes.* 2005; 54(Suppl 2):S32–9. S32–S9. [PubMed: 16306337]
46. Greenbaum CJ, Anderson AM, Dolan LM, Mayer-Davis EJ, Dabelea D, Imperatore G, et al. Preservation of beta-cell function in autoantibody-positive youth with diabetes. *Diabetes Care.* 2009; 32:1839–44. [PubMed: 19587365]
47. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. *Diabetes.* 2012; 61:2066–73. [PubMed: 22688329]
48. Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC. Characterization of residual beta cell function in long-standing type 1 diabetes. *Diabetes/metabolism research and reviews.* 2014; 30:154–62. [PubMed: 24115337]
49. Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. *Diabetologia.* 2014; 57:187–91. [PubMed: 24121625]
50. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. *Diabetes Care.* 2012; 35:465–70. [PubMed: 22355018]
51. Oram RA, McDonald TJ, Shields BM, Hudson MM, Shepherd MH, Hammersley S, et al. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. *Diabetes care.* 2015; 38:323–8. [PubMed: 25519449]
52. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. *Diabetes Care.* 2006; 29:643–9. [PubMed: 16505520]
53. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. *Diabetes.* 2010; 59:679–85. [PubMed: 20028949]
54. Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, et al. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). *Diabetes.* 2010; 59:2386–9. [PubMed: 20682683]
55. Diedisheim M, Mallone R, Boitard C, Larger E. Beta-cell mass in non-diabetic autoantibody-positive subjects: an analysis based on the nPOD database. *The Journal of clinical endocrinology and metabolism.* 2016; jc20153756.
56. Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, et al. beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. *The Journal of clinical investigation.* 2015; 125:1163–73. [PubMed: 25642774]
57. Reiner T, Thurber G, Gaglia J, Vinegoni C, Liew CW, Upadhyay R, et al. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. *ProcNatlAcadSciUSA.* 2011; 108:12815–20.
58. Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. *JClinInvest.* 2011; 121:442–5.
59. Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, et al. Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. *JClinEndocrinolMetab.* 2006; 91:1855–61.

60. Tauriainen S, Salmela K, Rantala I, Knip M, Hyoty H. Collecting high-quality pancreatic tissue for experimental study from organ donors with signs of beta-cell autoimmunity. *Diabetes Metab ResRev.* 2010; 26:585–92.
61. Oikarinen M, Tauriainen S, Honkanen T, Vuori K, Karhunen P, Vasama-Nolvi C, et al. Analysis of pancreas tissue in a child positive for islet cell antibodies. *Diabetologia.* 2008; 51:1796–802. [PubMed: 18696046]
62. In't Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers-Marichal M, et al. Screening for insulinitis in adult autoantibody-positive organ donors. *Diabetes.* 2007; 56:2400–4. [PubMed: 17563060]
63. Wiberg A, Granstam A, Ingvast S, Harkonen T, Knip M, Korsgren O, et al. Characterization of human organ donors testing positive for type 1 diabetes-associated autoantibodies. *Clinical and experimental immunology.* 2015; 182:278–88. [PubMed: 26313035]